Long-term depression (LTD) encompasses a family of synaptic plasticity mechanisms that can be triggered by the synaptic or pharmacological activation of glutamate receptors — in particular ...

NMDARs appear to be abnormally activated in depression. Whereas traditional ... significant potential in multiple additional central nervous system conditions, including movement disorders and ...

Pyrilamine: potentiates CNS depression with alcohol, other CNS depressants. Caution with warfarin, sedatives, or tranquilizers.

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

This review provides a comprehensive examination of how neuroendocrine disorders resulting from cholestasis influence the ...

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced ...

depression, and other CNS disorders. YTD Price Performance:-4.41% Average Trading Volume: 17,446 Technical Sentiment Consensus Rating: Sell Current Market Cap: C$407.5M For an in-depth examination ...